EPINEPHRINE
| Brand name | ADRENALIN |
|---|---|
| Active ingredient | EPINEPHRINE |
| Strength | 5MG/250ML (20MCG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | April 2023 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11083698 | March 2039 | use U-3567 |
| 11207280 | March 2039 | product |
| 12133837 | March 2039 | product |
| 10653646 | March 2039 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.